德展健康(000813.SZ)参股公司东方略合作研发项目新适应症获得临床试验批准

智通财经09-22

智通财经APP讯，德展健康(000813.SZ)公告，公司于近日收到公司参股公司北京东方略生物医药科技股份有限公司(简称“东方略”)的通知，东方略于近日收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》(编号 2024LP02122)，批准了其与美国 Inovio Pharmaceuticals, Inc.(简称 “Inovio 公司”)合作研发的VGX-3100项目针对 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2469213009?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-22 16:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2469213009","market":"us","top_or_hot":-1,"title":"德展健康(000813.SZ)参股公司东方略合作研发项目新适应症获得临床试验批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，德展健康(000813.SZ)公告，公司于近日收到公司参股公司北京东方略生物医药科技股份有限公司(简称“东方略”)的通知，东方略于近日收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》(编号 2024LP02122)，批准了其与美国 Inovio Pharmaceuticals, Inc.(简称 “Inovio 公司”)合作研发的VGX-3100项目针对 ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1185586.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>德展健康(000813.SZ)参股公司东方略合作研发项目新适应症获得临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n德展健康(000813.SZ)参股公司东方略合作研发项目新适应症获得临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-22 16:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1185586.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，德展健康(000813.SZ)公告，公司于近日收到公司参股公司北京东方略生物医药科技股份有限公司(简称“东方略”)的通知，东方略于近日收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》(编号 2024LP02122)，批准了其与美国 Inovio Pharmaceuticals, Inc.(简称 “Inovio 公司”)合作研发的VGX-3100项目针对 ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1185586.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000813","symbol_name":"德展健康","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1185586.html","article_id":"2469213009","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2469213009","pubTimestamp":1726993697,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，德展健康(000813.SZ)公告，公司于近日收到公司参股公司北京东方略生物医药科技股份有限公司(简称“东方略”)的通知，东方略于近日收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》(编号 2024LP02122)，批准了其与美国 Inovio Pharmaceuticals, Inc.(简称 “Inovio 公司”)合作研发的VGX-3100项目针对 HPV-16/18 相关肛门癌前病变的II期临床试验申请。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"000813":"德展健康","BK0060":"抗癌","BK0239":"医药制造","BK0114":"健康中国","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","03347":"泰格医药","BK1583":"高瓴概念"},"translate_title":"Dezhan Health (000813. SZ) joint-stock company Dongfanglue cooperative research and development project has obtained clinical trial approval for new indications","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000813":1,"03347":1},"content_text":"智通财经APP讯，德展健康(000813.SZ)公告，公司于近日收到公司参股公司北京东方略生物医药科技股份有限公司(简称“东方略”)的通知，东方略于近日收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》(编号 2024LP02122)，批准了其与美国 Inovio Pharmaceuticals, Inc.(简称 “Inovio 公司”)合作研发的VGX-3100项目针对 HPV-16/18 相关肛门癌前病变的II期临床试验申请。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2469213009"}